Kymera Therapeutics (KYMR) Net Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Net Cash Flow for 8 consecutive years, with -$212.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 603.21% year-over-year to -$212.9 million; the TTM figure through Mar 2026 stood at $54.1 million (up 1619.57% YoY), while the FY2025 annual figure was $236.8 million, up 2204.69% from the prior year.
• Net Cash Flow slipped to -$212.9 million in Q1 2026 per KYMR's latest filing, from $244.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $245.9 million in Q2 2025 and bottomed at -$222.9 million in Q3 2025.
• Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of $1.9 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow slumped 1470.87% — and 2025, when it jumped 2456.02%.
• Kymera Therapeutics' Net Cash Flow stood at -$87.2 million in 2022, then jumped by 133.16% to $28.9 million in 2023, then slumped by 66.99% to $9.5 million in 2024, then surged by 2456.02% to $244.1 million in 2025, then sank by 187.23% to -$212.9 million in 2026.
• Business Quant data shows KYMR's Net Cash Flow at -$212.9 million in Q1 2026, $244.1 million in Q4 2025, and -$222.9 million in Q3 2025.